Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance

By Chahardouli Bahram   Zaker Farhad   Mousavi Seied Asadollah   Kazemi Ahmad   Ostadali Mohammadreza   Nadali Fatemeh   Rostami Shahrbano   Alimoghaddam Kamran   Ghavamzade Ardeshir  

Hematology, Vol. 18, Iss. 3, 2013-05 ,pp. : 158-162

Maney Publishing

Access to resources Recommend Favorite

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

By Koh Youngil   Kim Inho   Yoon Sung-Soo   Kim Byoung   Kim Dae-Young   Lee Je-Hwan   Lee Kyoo-Hyung   Park Eunkyung   Kim Hyeoung-Joon   Sohn Sang   Joo Young   Kim Seok   Chung Jooseop   Shin Ho-Jin   Kim Sung-Hyun   Kim Chul   Song Hong   Kim Min   Hyun Myung   Ahn Jin   Jung Chul   Park Seonyang  

Annals of Hematology, Vol. 89, Iss. 7, 2010-07 ,pp. : 725-731

Springer Publishing Company

Access to resources Recommend Favorite

Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 18, Iss. 3, 2018-12 ,pp. : 234-238

Bentham Science Publishers

Access to resources Recommend Favorite

Μultiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia

By Galanopoulos A.  

Annals of Hematology, Vol. 88, Iss. 3, 2009-03 ,pp. : 281-282

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite